DGAP-News: 4SC to Highlight the Potential of its Oncology Compounds at the 22nd EORTC-NCI-AACR Symposium 'on Molecular Targets and Cancer Therapeutics'
(firmenpresse) - 4SC AG / Key word(s): Miscellaneous
16.11.2010 07:30
---------------------------------------------------------------------------
Planegg-Martinsried, Germany, 16 November, 2010 - 4SC (Frankfurt, Prime
Standard: VSC), a drug discovery and development company focused on
autoimmune and cancer indications, today announced that it will present
four posters and respective abstracts that highlight the development of its
lead oncology compound resminostat and several preclinical drug candidates
at the 22nd EORTC-NCI-AACR symposium from 16 - 19 November, 2010 in Berlin,
Germany. These data include an overview on the clinical development
activities of the pan-HDAC inhibitor resminostat, currently in Phase II
trials in hepatocellular cancer and Hodgkin's lymphoma, a profile of its
second, selective-HDAC inhibitor 4SC-202 and an introduction to 4SC-207, an
anti-mitotic cell cycle blocker.
'Our presence at EORTC underlines our commitment to developing oncology
candidates that will offer an improved and targeted standard of care for
cancer patients,' said Bernd Hentsch, Chief Development Officer, 4SC. 'We
have focused our resources over the last three years in order to establish
a pipeline of clinical and preclinical compounds targeting molecular
pathways for various tumour types and hold the promise to provide more
tailored treatment for patients.'
Poster Presentations by 4SC:
Resminostat (4SC-201):
Abstract: #540,
Poster Board: #076
Title: Clinical Phase II Development of Resminostat, a Novel HDAC Inhibitor
Session date and time: 19 Nov 2010, 8:00 AM - 9:30 AM, Poster session on
'Genetics and epigenetics'
Poster Presenter: Rüdiger Jankowsky, Anna Mais, Stefan W. Henning, Bernhard
Hauns, Bernd Hentsch
Abstract: #542
Poster board: #078
Title: Centralised Analysis of Phase I ECG Dataset of Resminostat, a New
Oral Histone Deacetylase Inhibitor (HDACi)
Session date and time: 19 Nov 2010, 8:00 AM - 9:30 AM, Poster session on
'Genetics and epigenetics'
Poster Presenter: Bernhard Hauns, Anna Mais, Rüdiger Jankowsky, Bernd
Hentsch, Wilhelm Haverkamp
4SC-202:
Abstract: #178
Poster board: #135
Title: Preclinical Characterization of 4SC-202, a novel isotype specific
HDAC inhibitor
Session date and time: 17 Nov 2010, 12:00 - 14:30 AM, Poster session on
'Molecular-targeted therapies-preclinical'
Poster Presenter: Stefan W. Henning, Robert Doblhofer, Hella Kohlhof,
Rüdiger Jankowsky, Thomas Maier, Thomas Beckers, Matthias Schmidt and Bernd
Hentsch
4SC-207:
Abstract: #501
Poster Board: #037
Title: 4SC-207, a novel and highly potent anti-mitotic agent, active also
on PgP expressing tumor cells resistant to other chemotherapeutic drugs,
induces complete tumor stasis in in vivo tumor models
Session date and time: 19 Nov 2010, 8:00 - 9:30 AM, Poster session on
'Cell-cycle-interactive agents'
Poster Presenter: Aldo Ammendola, Rolf Krauss, Robert Doblhofer, Stefan
Strobl, Svetlana Hamm, Matthias Schmidt, Petra Gimmnich, Klaus Pekari,
Astrid Zimmermann, Bernd Hentsch
- End -
About Resminostat (4SC-201)
Resminostat (4SC-201) is an oral pan-histone-deacetylase (HDAC) inhibitor.
HDAC inhibitors modify the DNA structure of tumour cells to cause their
differentiation and programmed cell death (apoptosis) and are therefore
considered to offer a mechanism of action that has the particular potential
to halt tumourprogression and induce tumour regression. Resminostat is
currently in a Phase II study as a second line treatment for advanced
hepatocellular carcinoma and as a third-line treatment in Hodgkin's
lymphoma. In a completed Phase I trial in patients with various different
cancer types, stable disease was achieved in over 50% of the patients,
whilst the treatment was well tolerated and showed a positive,
differentiating pharmacological profile to other drugs in this class.
About 4SC-202
This candidate is an oral, selective Class I histone-deacetylase (HDAC)
inhibitor. In contrast to the further advanced pan- HDAC inhibitor
resminostat it belongs to a different chemical class with a selective
inhibitory effect on Class I HDAC enzymes. 4SC-202 enables a dual attack on
malignant cancer cells as it exhibits a special anti-mitotic effect, which
makes this candidate particularly suitable for the treatment of cancer
types characterised by rapid tumour cell proliferation.
About 4SC-207
4SC-207 is a novel, orally available cell-cycle blocker (CCB) for the
treatment of chemotherapy resistant tumours. This anti-mitotic compound
inhibits the cell division of actively proliferating tumour cells. In
preclinical testing, apoptosis was observed in dividing cancer cells only,
rather than in non-proliferating cells. A prominent characteristic of
4SC-207 is its resistance breaking activity. 4SC-207 affects cancer cells
which are already resistant to taxanes and alkaloids.
About 4SC
4SC AG (ISIN DE0005753818) is a drug discovery and development company
focused on autoimmune and cancer indications. Vidofludimus (4SC-101), a
small molecule, is currently in a Phase IIb study in rheumatoid arthritis
and a Phase IIa exploratory study in inflammatory bowel disease. The
company's lead oncology compound, resminostat (4SC-201), a pan histone
deacetylase (HDAC) inhibitor, is in Phase II trials in hepatocellular
carcinoma and Hodgkin's lymphoma. Two further oncology compounds, 4SC-203
and 4SC-205, are in Phase I studies. 4SC develops drug candidates until
proof-of-concept in order to generate value creating partnerships with the
pharmaceutical industry in return for advance and milestone payments as
well as royalties.
Founded in 1997, 4SC has 94 employees and has been listed on the Prime
Standard of the Frankfurt Stock Exchange since December 2005.
For further information, please visit www.4sc.com.
For more information please contact:
4SC AG
Yvonne Alexander
Investor&Public Relations
Tel.: +49 (0) 89 70 07 63 - 66
yvonne.alexander(at)4sc.com
MC Services (Europe)
Raimund Gabriel
Tel.: +49 (0) 89 21 02 28 - 30
raimund.gabriel(at)mc-services.eu
The Trout Group (USA)
Chad Rubin
Tel.: +1 646 378 2947
crubin(at)troutgroup.com
Legal Note
This document may contain projections or estimates relating to plans and
objectives relating to our future operations, products, or services; future
financial results; or assumptions underlying or relating to any such
statements; each of which constitutes a forward-looking statement subject
to risks and uncertainties, many of which are beyond our control. Actual
results could differ materially, depending on a number of factors.
16.11.2010 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: 4SC AG
Am Klopferspitz 19a
82152 Martinsried
Deutschland
Phone: +49 (0)89 7007 63-0
Fax: +49 (0)89 7007 63-29
E-mail: public(at)4sc.com
Internet: www.4sc.de
ISIN: DE0005753818
WKN: 575381
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in München, Düsseldorf, Berlin, Stuttgart
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
Datum: 16.11.2010 - 07:30 Uhr
Sprache: Deutsch
News-ID 32627
Anzahl Zeichen: 0
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 289 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: 4SC to Highlight the Potential of its Oncology Compounds at the 22nd EORTC-NCI-AACR Symposium 'on Molecular Targets and Cancer Therapeutics'"
steht unter der journalistisch-redaktionellen Verantwortung von
4SC AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
